Findings of similar or greater benefit among patients with low/no PD-L1 expression versus high/intermediate PD-L1 expression with toripalimab plus chemotherapy were also observed in advanced NPC (JUPITER-02) and NSCLC (CHOICE-01) for both OS and PFS. Here, CD274 is linked to nasopharyngeal carcinoma.